US Stock Movers: Eli Lilly surged on October 29 as Q3 earnings exceeded expectations, revenue outlook was raised, and weight-loss drug saw strong growth.

Eli Lilly October 29 Major Surge Interpretation

Keywords: Q3 results beat expectations, raised revenue guidance, high growth in weight loss drugs

1. On October 29, Eli Lilly announced its third quarter 2026 financial report, with revenue of $24.4 billion, up 39% year-on-year, compared to market expectations of $22.52 billion. Adjusted earnings per share were $7.48, exceeding market expectations of $5.59.

2. On October 29, Eli Lilly raised its full-year 2026 revenue guidance from $85–87 billion to $91–92 billion, and increased its profit margin guidance from 49–50.5% to 52–52.5%. Due to R&D expenses related to business expansion in the third quarter, the full-year adjusted earnings per share guidance was lowered from $35.50–36.50 to $35–36.

3. On October 29, Eli Lilly's global sales of Mounjaro reached $10.723 billion in the third quarter, up 65% year-on-year; Zepbound sales reached $5.352 billion, up 49% year-on-year. In the U.S. market, Mounjaro sales were about $5 billion, up 41%, and Zepbound sales were about $5.3 billion, up 48%.

4. On October 29, Eli Lilly disclosed in its third quarter financial report that the head-to-head Phase 3 study of retatrutide for treating type 2 diabetes achieved positive topline results, meeting the primary endpoint and all key secondary endpoints. Industry news reported that after 80 weeks of treatment, the average maximum weight reduction reached up to 20.9%.

(Disclaimer: This content is collected and summarized from public information by AI technology and is for reference only. It does not constitute investment advice.)